Trevena announces publication of results from Phase III �Real World� safety study for oliceridine in The Journal of Pain Research.
Trevena, Inc. announced publication of results from the Phase III open-label safety study (ATHENA) for IV oliceridine in The Journal of Pain Research. The results highlight the safety and tolerability of oliceridine in the management of moderate-to-severe acute pain in a variety of surgical / medical settings and patient populations.
The publication, �ATHENA: A Phase III, Open Label Study of the Safety and Effectiveness of Oliceridine (TRV130), a G-Protein Selective Agonist at the �-Opioid Receptor, in Patients with Moderate to Severe Acute Pain Requiring Parenteral Opioid Therapy� with investigator and lead author, Sergio Bergese, M.D., Department of Anesthesiology, School of Medicine, Stony Brook University, is available online on Dove Medical Press.
�The results of this study show that oliceridine was generally safe and well-tolerated in a variety of surgical and medical conditions with acute pain. Additionally, oliceridine performed consistently in the patient population studied, including elderly and obese patients, who are at greater risk for developing opioid-related adverse effects,� said Dr. Bergese. �These findings suggest that oliceridine may represent a potential new treatment option for the management of moderate-to-severe acute pain where IV opioid therapy is warranted.�
Study Summary and Key Findings: This was a Phase III, multi-center, open-label study that evaluated the safety of oliceridine in 768 patients with moderate-to-severe acute pain. It was conducted in 41 sites in the United States, including ambulatory surgical centers, hospital-based outpatient and inpatient settings, and emergency departments. In order to study oliceridine in a broad, �real world� context where IV analgesics are typically used, the protocol was designed with broader patient eligibility criteria, concomitant treatment allowances, and mode of administration (both clinician-directed bolus and patient-controlled analgesia were permitted as clinically indicated). The average age of patients in this study was 54 years. 32% of patients were 65 years or older, and 46% were considered obese with a body mass index (BMI) of 30 kg/m2 or higher. The study included patients with a range of co-morbidities, including diabetes, chronic / cancer pain and obstructive sleep apnea. Patients with post-surgical acute pain comprised the majority of the study population (94%). The most common procedure types were orthopedic (30%), colorectal (15%) and gynecological (15%).
AEs were mostly of mild or moderate severity, and only 2% of patients discontinued treatment due to an AE. The most commonly reported adverse events (AEs) were nausea, vomiting, and constipation.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)